Products / Reagent / 92-1151
Contact a Specialist

ABT-737

ABT-737 is a small molecule BH3 mimetic inhibitor of the anti-apoptotic members of the BCL-2 family, selective for BCL-2, BCL-XL, and BCL-W (EC50=78.7, 30.3, and 197.8nM, respectively). Developed by Abbvie, it failed in clinical trials due to toxicity issues, but was proven efficacious with various radiation therapies in triggering apoptosis in cancer cells and xenografts.

Catalog No. Size Price Quantity
92-1151 5 mg $329.00
Please contact Customer Service at customerservicedrx@eurofins.com for European (EUR) or United Kingdom (GBP) pricing or log in to see your account-specific pricing.
Description
ABT-737
Compound Type
Antagonist
Storage
≤ -20◦C
Source
Synthetic
Cells were plated in a 384-well plate and incubated overnight at 37°C/5% CO₂ to allow the cells to attach and grow. Cells were then stimulated with a control compound, using the assay conditions described below. Following treatment, signal was detected using the InCELL Hunter Detection Kit according to the recommended protocol.